BitTech Research

BitTech, Inc.

BitTech Research

BitTech, Inc. conducts basic and applied research. This research is both company funded and funded via NIH research grants awarded to the company (see CV for NIH Research Grants awarded thus far).

The majority of BitTech Research to date has been in the area of human cancer. BitTech OncoLogic Corp. (BTOL®) was incorporated in April, 2000, to commercialize existing and future cancer technology developed by BitTech, Inc.

BitTech, Inc. considers initiating any project within the scope of its current research interests (see CV). The Company primarily uses the budding yeast Saccharomyces cerevisae as a model eukaryote. Other cell types or organisms will be utilized when appropriate for the project.